Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria
- 1 March 1987
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 31 (3) , 463-466
- https://doi.org/10.1128/aac.31.3.463
Abstract
A-56268 was compared with erythromycin, roxithromycin (RU 28965), and perorally administered antimicrobial agents. Its in vitro activity was similar to that of erythromycin and slightly greater than that of roxithromycin, with beta-hemolytic streptococci and Streptococcus pneumoniae inhibited by less than 2 micrograms of A-56268 per ml (50% inhibited by 0.06 microgram/ml). Streptococcus pyogenes, S. agalactiae, S. Pneumoniae, and S. faecalis resistant to erythromycin were resistant to A-56268, and 4 micrograms/ml inhibited 90% of Haemophilus influenzae isolates.This publication has 4 references indexed in Scilit:
- Erythromycin: A Microbial and Clinical Perspective After 30 Years of Clinical Use (Second of Two Parts)Mayo Clinic Proceedings, 1985
- In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugsAntimicrobial Agents and Chemotherapy, 1983
- Effect of Several Components of Anaerobic Incubation on Antibiotic Susceptibility Test ResultsAntimicrobial Agents and Chemotherapy, 1972